Stocks
Cardiovascular Systems Financial Statements () |
||||||||||
| Cardiovascular Systemssmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | LTM ? | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 20.08.2020 | 19.08.2021 | 31.12.2021 | 30.06.2022 | 18.08.2022 | 09.02.2023 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 236.5 | 259.0 | 236.2 | 236.2 | 183.7 | ||||
| Operating Income, bln rub | -26.8 | -11.9 | -35.8 | -35.8 | -28.9 | |||||
| EBITDA, bln rub | ? | -25.5 | -10.7 | -31.6 | -34.5 | -26.4 | ||||
| Net profit, bln rub | ? | -27.2 | -13.4 | -36.9 | -36.9 | -28.2 | ||||
| OCF, bln rub | ? | -12.8 | -0.884 | 0.000 | -24.3 | -27.0 | ||||
| CAPEX, bln rub | ? | 4.09 | 3.95 | 0.000 | 4.22 | 3.73 | ||||
| FCF, bln rub | ? | -16.9 | -4.84 | 0.000 | -28.5 | -30.8 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| OPEX, bln rub | 214.6 | 209.8 | 207.2 | 208.6 | 161.2 | |||||
| Cost of production, bln rub | 48.8 | 61.1 | 63.4 | 63.4 | 51.4 | |||||
| R&D, bln rub | 43.4 | 41.1 | 36.7 | 36.7 | 27.4 | |||||
| Interest expenses, bln rub | 1.97 | 1.74 | 0.000 | 1.63 | 1.22 | |||||
| Assets, bln rub | 339.5 | 352.6 | 326.4 | 0.323 | 322.7 | 311.5 | ||||
| Net Assets, bln rub | ? | 268.8 | 271.0 | 259.5 | 0.249 | 249.5 | 239.4 | |||
| Debt, bln rub | 20.8 | 20.6 | 0.000 | 0.000 | 20.3 | 20.1 | ||||
| Cash, bln rub | 232.2 | 207.0 | 176.5 | 0.160 | 159.8 | 132.0 | ||||
| Net debt, bln rub | -211.3 | -186.4 | -176.5 | -0.16 | -139.5 | -111.9 | ||||
| Ordinary share price, rub | 31.6 | 42.7 | 18.8 | 14.4 | 14.4 | 13.6 | ||||
| Number of ordinary shares, mln | 34.3 | 38.8 | 39.2 | 39.2 | 39.7 | |||||
| Market cap, bln rub | 1 081 | 1 656 | 0 | 563 | 563 | 540 | ||||
| EV, bln rub | ? | 870 | 1 470 | -177 | 563 | 424 | 428 | |||
| Book value, bln rub | 252 | 256 | 243 | 0 | 234 | 224 | ||||
| EPS, rub | ? | -0.79 | -0.35 | -0.94 | -0.94 | -0.71 | ||||
| FCF/share, rub | -0.49 | -0.12 | 0.00 | -0.73 | -0.78 | |||||
| BV/share, rub | 7.36 | 6.58 | 0.01 | 5.96 | 5.66 | |||||
| EBITDA margin, % | ? | -10.8% | -4.14% | -13.4% | -14.6% | -14.3% | ||||
| Net margin, % | ? | -11.5% | -5.18% | -15.6% | -15.6% | -15.4% | ||||
| FCF yield, % | ? | -1.56% | -0.29% | 0.00% | 0.00% | -5.06% | -5.69% | |||
| ROE, % | ? | -10.1% | -4.95% | 0.00% | -14 804% | -14.8% | -11.8% | |||
| ROA, % | ? | -8.02% | -3.81% | 0.00% | -11 446% | -11.4% | -9.06% | |||
| P/E | ? | -39.7 | -123.4 | -15.3 | -15.3 | -19.1 | ||||
| P/FCF | -64.2 | -342.3 | -19.8 | -17.6 | ||||||
| P/S | ? | 4.57 | 6.40 | 2.38 | 2.38 | 2.94 | ||||
| P/BV | ? | 4.29 | 6.48 | 0.00 | 2 410 | 2.41 | 2.41 | |||
| EV/EBITDA | ? | -34.1 | -137.1 | -17.8 | -12.3 | -16.3 | ||||
| Debt/EBITDA | 8.28 | 17.4 | 0.01 | 4.05 | 4.25 | |||||
| R&D/CAPEX, % | 1 061% | 1 038% | 870.1% | 734.4% | ||||||
| CAPEX/Revenue, % | 1.73% | 1.53% | 0.00% | 1.79% | 2.03% | |||||
| Cardiovascular Systems shareholders | ||||||||||
